Search results for "CHLOROQUINE"

showing 10 items of 65 documents

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

2020

Purpose To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. Materials and methods MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19. Results Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two ‘some concerns’ and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderat…

ICU Intensive care unit;medicine.medical_treatmentCritical Care and Intensive Care MedicineRR Risk Ratio0302 clinical medicineChloroquineRCT Randomized clinical trialMedicineHCQ Hydroxychloroquine;Prospective StudiesProspective cohort studyChloroquine COVID-19 Hydroxychloroquine Mortality SARS-CoV-2ChloroquineECG Electrocardiogram;Rob2 Revised tool for Risk of Bias in randomized trials;CI Confidence interval;Coronavirus InfectionsPost-Exposure ProphylaxisHydroxychloroquinemedicine.drugmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralMEDLINEContext (language use)Antiviral AgentsArticleWHO World Health OrganizationBetacoronavirus03 medical and health sciencesInternal medicineHumansMortalityCOVID-19 Coronavirus disease 2019;Post-exposure prophylaxisPandemicsRetrospective StudiesCQ Chloroquine;SARS-CoV-2ROBINS-I Risk of Bias in Non-randomized Studies of Interventions;business.industryCOVID-19030208 emergency & critical care medicineHydroxychloroquineRetrospective cohort studyHCWs Healthcare workers;NOS Newcastle Ottawa Scale;COVID-19 Drug Treatment030228 respiratory systembusinessHR Hazard Ratio;Journal of Critical Care
researchProduct

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53

2020

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy. Approximately 85% of pancreatic cancers are classified as PDACs. The survival of PDAC patients is very poor and only 5–10% of patients survive 5 years after diagnosis. Mutations at the KRAS and TP53 gene are frequently observed in PDAC patients. The PANC-28 cell line lacks wild-type (WT) TP53. In the following study, we have investigated the effects of restoration of WT TP53 activity on the sensitivity of PANC-28 pancreatic cancer cells to various drugs which are used to treat PDAC patients as well as other cancer patients. In addition, we have examined the effects of signal transduction inhibitors which tar…

Male0301 basic medicineDrugCancer ResearchmiRsendocrine system diseasesmedia_common.quotation_subjectSignal transduction inhibitorsTargeted therapeuticAntineoplastic AgentsMalignancymedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineChloroquinePancreatic cancerGeneticsmedicineHumansTP53Molecular BiologyneoplasmsSignal transduction inhibitorTargeted therapeuticsCell Proliferationmedia_commontarget therapeuticsCell growthbusiness.industryCancermedicine.diseasedigestive system diseasesMetforminPancreatic Neoplasms030104 developmental biology030220 oncology & carcinogenesisDietary SupplementsMutationCancer researchmiRs.Molecular MedicineFemaleKRASTumor Suppressor Protein p53businessSignal Transductionmedicine.drugDrug sensitivity
researchProduct

Morphological studies on CLN2

2001

Electron microscopic, fluorescence microscopic, and immunohistochemical studies earlier performed on archivalcerebral tissue from Max Bielchowsky's original three patients revealed curvilinear bodies rich in subunit C of mitochondrial ATP synthase (SCMAS). Recent progress in the elucidation of CLN2, i.e. identification of the defective lysosomal enzyme tripeptidyl-peptidase I (TPP-I) and mutations in the CLN2 gene have further corroborated earlier data. Immunohistochemically the absence of the TPP-I protein could be confirmed in the archival tissues using pathological controls. Unlike biochemistry, immunohistochemistry enables examination of these archival tissues elucidating the causative …

MaleCell typePathologymedicine.medical_specialtyProtein subunitEncephalopathyBiologymedicine.disease_causeAminopeptidasesNeuronal Ceroid-LipofuscinosesChloroquineEndopeptidasesmedicineHumansChildDipeptidyl-Peptidases and Tripeptidyl-PeptidasesMyopathyGeneMutationTripeptidyl-Peptidase 1BrainGeneral MedicineMitochondrial Proton-Translocating ATPasesmedicine.diseaseImmunohistochemistryProton-Translocating ATPasesMutationPediatrics Perinatology and Child HealthImmunohistochemistryFemaleNeurology (clinical)Serine Proteasesmedicine.symptomPeptide Hydrolasesmedicine.drugEuropean Journal of Paediatric Neurology
researchProduct

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering

2021

The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and experimental studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February–May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases, and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distan…

MaleMedicine (General)Antimalarial030204 cardiovascular system & hematologySeverity of Illness IndexHospital Mortality.0302 clinical medicineRetrospective Studie80 and overCluster Analysis030212 general & internal medicineHospital MortalityAged; Aged 80 and over; Antimalarials; COVID-19; Cluster Analysis; Female; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Hospital MortalityAged 80 and overMiddle AgedTreatment OutcomeItalyFemaleBiotechnologymedicine.drugResearch ArticleHydroxychloroquinemedicine.medical_specialtyArticle SubjectBiomedical EngineeringRenal functionHealth Informatics03 medical and health sciencesAntimalarialsR5-920Internal medicineDiabetes mellitusSeverity of illnessmedicineMedical technologyHumansR855-855.5AgedRetrospective StudiesCluster Analysibusiness.industrySARS-CoV-2CancerCOVID-19Retrospective cohort studyHydroxychloroquinemedicine.diseaseObesityCOVID-19 Drug TreatmentSurgeryObservational studybusinessJournal of Healthcare Engineering
researchProduct

Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model

2021

Limb-girdle muscular dystrophy D2 (LGMDD2) is an ultrarare autosomal dominant myopathy caused by mutation of the normal stop codon of the TNPO3 nuclear importin. The mutant protein carries a 15 amino acid C-terminal extension associated with pathogenicity. Here we report the first animal model of the disease by expressing the human mutant TNPO3 gene in Drosophila musculature or motor neurons and concomitantly silencing the endogenous expression of the fly protein ortholog. A similar genotype expressing wildtype TNPO3 served as a control. Phenotypes characterization revealed that mutant TNPO3 expression targeted at muscles or motor neurons caused LGMDD2-like phenotypes such as muscle degener…

MaleMutantBiochemistryAnimals Genetically ModifiedMutant proteinAutophagyGeneticsmedicineAnimalsHumansGene silencingMuscular dystrophyMyopathyMolecular BiologyMotor NeuronsbiologyMusclesAutophagyChloroquinebeta Karyopherinsmedicine.diseasebiology.organism_classificationMuscle atrophyCell biologySurvival RateDisease Models AnimalMuscular AtrophyDrosophila melanogasterPhenotypeMuscular Dystrophies Limb-GirdleInsect HormonesFemalemedicine.symptomDrosophila melanogasterLocomotionBiotechnologyThe FASEB Journal
researchProduct

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020

2020

Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day–17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.

MalePediatricsEpidemiologyProtease InhibitorComorbiditymedicine.disease_causeClinical Laboratory TechniqueSevere Acute Respiratory SyndromeDisease OutbreaksFeces0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaCOVID-19 TestingRetrospective StudiePandemic030212 general & internal medicineViralChildCoronavirusPediatricDisease OutbreakCoinfectionHospitals PediatricSettore MED/38HospitalsDiarrheaTreatment OutcomeSARS-CoV-2 infection; children; covid-19; hydroxychloroquine; pneumonia; Adolescent; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; SARS-CoV-2; Severe Acute Respiratory Syndrome; Treatment OutcomeItalyChild PreschoolCoinfectionFemalemedicine.symptomCoronavirus InfectionsRapid CommunicationHumanDiarrheamedicine.medical_specialtyCOVID-19; ItalyhydroxychloroquineAdolescentFeverCoronaviruPneumonia ViralAntiviral Agents03 medical and health sciencesBetacoronavirusImmunocompromised Hostchildren030225 pediatricsVirologyIntensive caremedicineHumanspneumoniaProtease InhibitorsPreschoolPandemicsRetrospective StudiesAntiviral Agentchildren; covid-19; hydroxychloroquine; pneumonia; SARS-CoV-2 infection; Adolescent; Antiviral Agents; Betacoronavirus; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; Severe Acute Respiratory Syndrome; Treatment OutcomeNoninvasive VentilationBetacoronaviruPandemicbusiness.industryClinical Laboratory TechniquesCoronavirus InfectionSARS-CoV-2pneumonia.SARS-CoV-2 infectionPublic Health Environmental and Occupational HealthInfant NewbornCOVID-19InfantRetrospective cohort studymedicine.diseaseNewbornComorbidityCoronavirusPneumoniaChronic DiseaseFecebusiness
researchProduct

Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.

2015

Several bicyclic compounds, 3-azabicyclo[3.2.2]nonanes, have been prepared. The new compounds were tested for their activities against one strain of the causative organism of Malaria tropica, Plasmodium falciparum K1, which is resistant against chloroquine and pyrimethamine. In addition, their cytotoxicity and their activity against the pathogen of the East African form of sleeping sickness, Trypanosoma brucei rhodesiense, were investigated. Structure-activity relationships are discussed considering data of readily prepared compounds. For the first time, a distinct in vivo activity was observed against Plasmodium berghei in a mouse model. The active compound was further investigated.

MaleTrypanosoma brucei rhodesiensemedicine.drug_classPlasmodium bergheiClinical BiochemistryPlasmodium falciparumAntiprotozoal AgentsPharmaceutical ScienceAdministration OralBiochemistryMiceStructure-Activity RelationshipParasitic Sensitivity TestsChloroquineparasitic diseasesDrug DiscoverymedicineAnimalsPlasmodium bergheiTissue DistributionMolecular BiologyPathogenbiologyBicyclic moleculeDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryPlasmodium falciparumTrypanosoma brucei rhodesiensebiology.organism_classificationRatsDisease Models AnimalPyrimethamineTrypanosomiasis AfricanBiochemistryInjections IntravenousAntiprotozoalMolecular MedicineAzabicyclo Compoundsmedicine.drugBioorganicmedicinal chemistry letters
researchProduct

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian…

2020

Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatme…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquineEuropean journal of internal medicine
researchProduct